Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Becker

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Leukemia|February 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)Kirsi Manz, Florian H Heidel, Steffen Koschmieder, et al.
Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Annals of Hematology|June 22, 2018
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trialsFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
Blood Advances|March 23, 2021
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantationNico Gagelmann, Anita Badbaran, Dietrich W Beelen, et al.
Hemasphere|April 2, 2025
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignanciesJohn G Gribben, Leticia Quintanilla-Martinez, Simon Crompton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2010
Dose escalation of lenalidomide in relapsed or refractory acute leukemiasWilliam Blum, Rebecca B Klisovic, Heiko Becker, et al.
Leukemia|February 25, 2025
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment - an intraindividual analysis by the German Study Group for MPN (GSG-MPN)Kirsi Manz, Florian H Heidel, Steffen Koschmieder, et al.
Blood Advances|July 12, 2018
Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remissionSumithira Vasu, Jessica Kohlschmidt, Krzysztof Mrózek, et al.
Annals of Hematology|June 22, 2018
Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15-60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trialsFrédéric Baron, Marian Stevens-Kroef, Michal Kicinski, et al.
Blood Advances|March 23, 2021
A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantationNico Gagelmann, Anita Badbaran, Dietrich W Beelen, et al.
Hemasphere|April 2, 2025
European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignanciesJohn G Gribben, Leticia Quintanilla-Martinez, Simon Crompton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B studyHeiko Becker, Guido Marcucci, Kati Maharry, et al.
Haematologica|June 11, 2011
Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyHeiko Becker, Kati Maharry, Michael D Radmacher, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2010
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabineWilliam Blum, Ramiro Garzon, Rebecca B Klisovic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2013
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patientsGuido Marcucci, Kati S Maharry, Klaus H Metzeler, et al.
Pageof 10